- Home
- NRIX vs NXRT Comparison
NRIX vs NXRT Comparison
Compare NRIX & NXRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- NXRT
- Stock Information
- Founded
- NRIX 2009
- NXRT 2014
- Country
- NRIX United States
- NXRT United States
- Employees
- NRIX N/A
- NXRT N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- NXRT Real Estate Investment Trusts
- Sector
- NRIX Health Care
- NXRT Real Estate
- Exchange
- NRIX Nasdaq
- NXRT Nasdaq
- Market Cap
- NRIX 1.1B
- NXRT 957.7M
- IPO Year
- NRIX 2020
- NXRT N/A
- Fundamental
- Price
- NRIX $9.64
- NXRT $37.13
- Analyst Decision
- NRIX Strong Buy
- NXRT Buy
- Analyst Count
- NRIX 17
- NXRT 6
- Target Price
- NRIX $30.71
- NXRT $46.33
- AVG Volume (30 Days)
- NRIX 999.6K
- NXRT 126.8K
- Earning Date
- NRIX 04-08-2025
- NXRT 04-29-2025
- Dividend Yield
- NRIX N/A
- NXRT 5.44%
- EPS Growth
- NRIX N/A
- NXRT N/A
- EPS
- NRIX N/A
- NXRT N/A
- Revenue
- NRIX $56,417,000.00
- NXRT $255,529,000.00
- Revenue This Year
- NRIX $15.73
- NXRT $0.06
- Revenue Next Year
- NRIX N/A
- NXRT $5.96
- P/E Ratio
- NRIX N/A
- NXRT N/A
- Revenue Growth
- NRIX N/A
- NXRT N/A
- 52 Week Low
- NRIX $8.18
- NXRT $30.98
- 52 Week High
- NRIX $29.56
- NXRT $48.37
- Technical
- Relative Strength Index (RSI)
- NRIX 36.33
- NXRT 48.87
- Support Level
- NRIX $11.05
- NXRT $36.19
- Resistance Level
- NRIX $11.56
- NXRT $38.08
- Average True Range (ATR)
- NRIX 0.64
- NXRT 0.92
- MACD
- NRIX -0.04
- NXRT 0.21
- Stochastic Oscillator
- NRIX 18.45
- NXRT 47.20
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About NXRT NexPoint Residential Trust Inc.
NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.